XML 54 R33.htm IDEA: XBRL DOCUMENT
v3.25.1

STOCKHOLDERS EQUITY (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2024
STOCKHOLDERS' EQUITY [Abstract] |
Warrants Outstanding | The following table summarizes information about warrants outstanding as of December 31, 2024, 2023 and 2022:
|  | Shares |  |  | Weighted Average Exercise Price |
Warrants outstanding at December 31, 2021 |  |  | 4,528,160 |  |  | $ | 2.82 |
Expired |  |  | (106,059 | ) |  | $ | 8.23 |
Granted |  |  | 9,103,047 |  |  | $ | 1.65 |
Exercised |  |  | - |  |  | $ | - |
Warrants outstanding at December 31, 2022 |  |  | 13,525,148 |  |  | $ | 1.99 |
Expired |  |  | (24,800 | ) |  | $ | 6.37 |
Granted |  |  | 2,391,244 |  |  | $ | 3.26 |
Exercised |  |  | (3,388,686 | ) |  | $ | 1.65 |
Warrants outstanding at December 31, 2023 |  |  | 12,502,906 |  |  | $ | 2.32 |
Expired |  |  | (227,650 | ) |  | $ | 4.21 |
Granted |  |  | - |  |  | $ | - |
Exercised |  |  | (11,308,702 | ) |  | $ | 2.31 |
Warrants outstanding at December 31, 2024 |  |  | 966,554 |  |  | $ | 1.98 |
Schedule of Assumptions | The grant date fair values of stock options awarded during the years ended December 31, 2024, 2023 and 2022 were determined using the Black-Scholes option pricing model with the following assumptions:
|  | Years Ended |
|  | December 31, 2024 |  |  | December 31, 2023 |  |  | December 31, 2022 |
Expected term |  | 5.5-6.3 years |  |  | 5.5-6.3 years |  |  | 5.5-6.3 years |
Volatility |  |  | 66 | % |  |  | 68 | % |  |  | 68 | %
Dividend yield |  |  | 0.0 |  |  |  | 0.0 |  |  |  | 0.0 |
Risk-free interest rate |  |  | 4.16-4.39 | % |  |  | 4.20-4.62 | % |  |  | 1.72-1.73 | %
Schedule of Option Activity | The following table summarizes information about stock options outstanding as of December 31, 2024, 2023 and 2022:
|  | Shares |  |  | Weighted Average Exercise Price |
Options outstanding, vested and expected to vest at December 31, 2021 |  |  | 7,862,722 |  |  | $ | 3.93 |
Forfeited |  |  | (31,540 | ) |  | $ | 2.37 |
Expired |  |  | (700,324 | ) |  | $ | 6.86 |
Granted |  |  | 1,194,032 |  |  | $ | 1.67 |
Exercised |  |  | (68,679 | ) |  | $ | 2.55 |
Options outstanding, vested and expected to vest at December 31, 2022 |  |  | 8,256,211 |  |  | $ | 3.37 |
Forfeited |  |  | (99,345 | ) |  | $ | 2.73 |
Expired |  |  | (262,940 | ) |  | $ | 6.42 |
Granted |  |  | 1,826,380 |  |  | $ | 3.36 |
Exercised |  |  | (3,814,122 | ) |  | $ | 3.15 |
Options outstanding, vested and expected to vest at December 31, 2023 |  |  | 5,906,184 |  |  | $ | 3.38 |
Forfeited |  |  | (30,094 | ) |  | $ | 3.36 |
Expired |  |  | (246,067 | ) |  | $ | 7.01 |
Granted |  |  | 1,531,635 |  |  | $ | 6.40 |
Exercised |  |  | (2,020,142 | ) |  | $ | 3.90 |
Options outstanding, vested and expected to vest at December 31, 2024 |  |  | 5,141,516 |  |  | $ | 3.90 |
Options exercisable |  |  | 2,657,932 |  |  | $ | 3.03 |
Summary of Outstanding and Exercisable Options by Price Range | The following table summarizes additional information regarding outstanding and exercisable options under the stock option plans at December 31, 2024:
|  |  | Stock Options Outstanding |  |  | Stock Options Exercisable |
Range of Exercise Prices |  |  | Options Outstanding |  |  | Weighted Average Remaining Contractual Life (Years) |  |  | Weighted Average Exercise Price |  |  | Aggregate Intrinsic Value ($000’s) |  |  | Options Outstanding |  |  | Weighted Average Remaining Contractual Life (Years) |  |  | Weighted Average Exercise Price |  |  | Aggregate Intrinsic Value ($000’s) |
$1.10 - $1.67 |  |  |  | 981,093 |  |  |  | 6.8 |  |  | $ | 1.60 |  |  | $ | 15,252 |  |  |  | 676,542 |  |  |  | 6.6 |  |  | $ | 1.58 |  |  | $ | 10,532 |
$1.73 - $2.60 |  |  |  | 629,655 |  |  |  | 5.7 |  |  | $ | 2.32 |  |  |  | 9,336 |  |  |  | 585,771 |  |  |  | 5.6 |  |  | $ | 2.33 |  |  |  | 8,683 |
$2.67 - $4.01 |  |  |  | 1,809,746 |  |  |  | 6.6 |  |  | $ | 3.41 |  |  |  | 24,868 |  |  |  | 1,012,271 |  |  |  | 5.4 |  |  | $ | 3.46 |  |  |  | 13,863 |
$4.09 - $6.14 |  |  |  | 1,264,083 |  |  |  | 8.1 |  |  | $ | 5.35 |  |  |  | 14,913 |  |  |  | 361,848 |  |  |  | 5.4 |  |  | $ | 5.23 |  |  |  | 4,312 |
$6.54 - $9.81 |  |  |  | 307,828 |  |  |  | 9.0 |  |  | $ | 6.60 |  |  |  | 3,248 |  |  |  | 7,500 |  |  |  | 0.6 |  |  | $ | 8.98 |  |  |  | 61 |
$10.80 - $17.49 |  |  |  | 149,111 |  |  |  | 8.7 |  |  | $ | 8.74 |  |  |  | 500 |  |  |  | 14,000 |  |  |  | 0.1 |  |  | $ | 10.80 |  |  |  | 89 |
|  |  |  | 5,141,516 |  |  |  | 7.1 |  |  | $ | 3.90 |  |  | $ | 68,117 |  |  |  | 2,657,932 |  |  |  | 5.7 |  |  | $ | 3.03 |  |  | $ | 37,540 |
Schedule of Unvested RSU Activity | A summary of the Company’s unvested RSU activity and related information is as follows:
|  | Shares |  |  | Weighted Average Grant Date Fair Value |
Balance at December 31, 2021 |  |  | 4,485,133 |  |  | $ | 1.34 |
Granted |  |  | 1,174,266 |  |  | $ | 1.74 |
Vested |  |  | (2,727,412 | ) |  | $ | 1.25 |
Forfeited |  |  | (65,000 | ) |  | $ | 1.40 |
Balance at December 31, 2022 |  |  | 2,866,987 |  |  | $ | 1.59 |
Granted |  |  | 3,389,760 |  |  | $ | 3.42 |
Vested |  |  | (1,199,445 | ) |  | $ | 1.63 |
Forfeited |  |  | (400,005 | ) |  | $ | 2.71 |
Balance at December 31, 2023 |  |  | 4,657,297 |  |  | $ | 2.81 |
Granted |  |  | 3,278,688 |  |  | $ | 7.44 |
Vested |  |  | (1,886,463 | ) |  | $ | 2.50 |
Forfeited |  |  | (303,532 | ) |  | $ | 3.92 |
Balance at December 31, 2024 |  |  | 5,745,990 |  |  | $ | 5.50 |
Schedule of Stock-Based Compensation Expense | Total stock-based compensation expense for all awards granted under the Company’s equity incentive plans for the years ended December 31, 2024, 2023 and 2022 was as follows (in thousands):
|  | Year Ended December 31, |
(in thousands) |  | 2024 |  |  | 2023 |  |  | 2022 |
Research and development |  | $ | 98 |  |  | $ | 40 |  |  | $ | 19 |
Plasma center operating expenses |  |  | 184 |  |  |  | 146 |  |  |  | 82 |
Selling, general and administrative |  |  | 11,720 |  |  |  | 5,331 |  |  |  | 4,717 |
Cost of product revenue |  |  | 1,614 |  |  |  | 670 |  |  |  | 397 |
Total stock-based compensation expense |  | $ | 13,616 |  |  | $ | 6,187 |  |  | $ | 5,215 |

X
- References No definition available. + Details
Name: | us-gaap_EquityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (f)(2) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1 + Details
Name: | us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the change in restricted stock units (RSUs). + References No definition available. + Details
Name: | us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration